| TITLE |
DATE |
| Orexigen Therapeutics to Present at the Lazard Capital Markets Healthcare Conference |
11-Nov-2011 |
| Orexigen® Therapeutics Reports Third Quarter Financial Results |
8-Nov-2011 |
| Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society |
3-Oct-2011 |
| Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society |
29-Sep-2011 |
| Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference |
26-Sep-2011 |
| Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® |
20-Sep-2011 |
| Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results |
8-Aug-2011 |
| Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA |
3-Jun-2011 |
| Orexigen® Therapeutics Schedules June 3, 2011 Webcast and Conference Call to Provide a Regulatory Update on Contrave® NDA |
1-Jun-2011 |
| Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results |
9-May-2011 |
| Orexigen® Therapeutics Schedules May 9, 2011 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2011 |
2-May-2011 |
| Orexigen(R) Therapeutics Announces Upcoming Data Presentations at The American College of Obstetricians and Gynecologists Annual Clinical Meeting |
26-Apr-2011 |
| Orexigen(R) Therapeutics Presents Additional Contrave(R) Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring |
4-Apr-2011 |
| Orexigen(R) Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting |
29-Mar-2011 |
| Orexigen(R) Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results |
10-Mar-2011 |
| Orexigen(R) Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010 |
3-Mar-2011 |
| Orexigen(R) Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer |
17-Feb-2011 |
| Orexigen(R) Therapeutics Announces Corporate Realignment |
9-Feb-2011 |
| FDA Issues Complete Response to New Drug Application for Contrave(R) for the Management of Obesity |
1-Feb-2011 |
| Orexigen(R) Therapeutics to Present at JP Morgan Healthcare Conference |
6-Jan-2011 |
| Orexigen(R) Therapeutics' Investigational Drug Contrave(R) Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity |
7-Dec-2010 |
| Orexigen(R) Therapeutics Reports Third Quarter 2010 Financial Results |
3-Nov-2010 |
| Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) |
28-Oct-2010 |
| Orexigen(R) Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010 |
28-Oct-2010 |
| Orexigen(R) Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society |
4-Oct-2010 |
| Orexigen(R) Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference |
24-Sep-2010 |
| Orexigen(R) Therapeutics to Speak at UBS Global Life Sciences Conference |
16-Sep-2010 |
| Orexigen(R) Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference |
10-Sep-2010 |
| Orexigen(R) Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave(R) in North America |
2-Sep-2010 |
| Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
27-Aug-2010 |
| Orexigen(R) Therapeutics to Speak at Canaccord Genuity Global Growth Conference |
6-Aug-2010 |
| Orexigen(R) Therapeutics Reports Second Quarter 2010 Financial and Operational Results |
5-Aug-2010 |
| Orexigen(R) Therapeutics COR-BMOD Study Published in the Journal Obesity |
3-Aug-2010 |
| Orexigen(R) Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet |
29-Jul-2010 |
| Orexigen(R) Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010 |
29-Jul-2010 |
| Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression |
26-Jun-2010 |
| Orexigen(R) Therapeutics Presents New Data Showing Contrave(R) Significantly Lowers Weight, Improves Blood Glucose Control in Obese Patients With Type 2 Diabetes |
25-Jun-2010 |
| Orexigen(R) Therapeutics Announces Date of FDA Advisory Committee Review of Contrave(R) for the Treatment of Obesity |
23-Jun-2010 |
| Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association Annual Scientific Meeting |
21-Jun-2010 |
| Orexigen(R) Therapeutics Announces Assignment of January 31, 2011 PDUFA Date for Contrave(R) New Drug Application |
17-Jun-2010 |
| Orexigen(R) Therapeutics to Speak at Jefferies 2010 Global Life Sciences Conference |
4-Jun-2010 |
| Orexigen(R) Therapeutics Announces FDA Acceptance of Contrave(R) New Drug Application for the Treatment of Obesity |
1-Jun-2010 |
| OREXIGEN(R) Therapeutics Reports First Quarter 2010 Financial and Operational Results |
10-May-2010 |
| Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference |
10-May-2010 |
| Orexigen(R) Therapeutics Schedules May 10, 2010 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2010 |
6-May-2010 |
| Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors |
21-Apr-2010 |
| Orexigen(R) Therapeutics Submits Contrave(R) New Drug Application to FDA for the Treatment of Obesity |
31-Mar-2010 |
| Orexigen(R) Therapeutics to Speak at Barclays Capital 2010 Global Healthcare Conference |
18-Mar-2010 |
| Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) |
12-Mar-2010 |
| Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results |
9-Mar-2010 |
| Orexigen(R) Therapeutics to Speak at Cowen & Company Healthcare Conference |
5-Mar-2010 |
| Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009 |
4-Mar-2010 |
| Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors |
2-Mar-2010 |
| Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) |
1-Mar-2010 |
| Orexigen(R) Therapeutics to Speak at BIO CEO and Investor Conference |
3-Feb-2010 |
| Orexigen(R) Therapeutics to Present at JP Morgan Healthcare Conference |
7-Jan-2010 |
| Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635 |
23-Dec-2009 |
| Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) |
24-Nov-2009 |
| Four Senior Executives Join Orexigen(R) Therapeutics Management Team |
23-Nov-2009 |
| Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference |
12-Nov-2009 |
| Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results |
4-Nov-2009 |
| Orexigen(R) Therapeutics Schedules November 4, 2009 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2009 |
29-Oct-2009 |
| Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society |
27-Oct-2009 |
| Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk |
24-Oct-2009 |
| Orexigen(R) Therapeutics Announces Contrave(R) Data Presentations at Annual Scientific Meeting of The Obesity Society |
21-Oct-2009 |
| Orexigen(R) Therapeutics to Speak at JMP Securities Healthcare Focus Conference |
1-Oct-2009 |
| Orexigen(R) Therapeutics Phase 2b Trial for Empatic(TM) Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients |
30-Sep-2009 |
| Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM) |
29-Sep-2009 |
| Orexigen(R) Therapeutics to Speak at UBS Global Life Sciences Conference |
16-Sep-2009 |
| Orexigen(R) Therapeutics to Speak at Upcoming Conferences |
9-Sep-2009 |
| Orexigen(R) Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference |
3-Sep-2009 |
| Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer |
24-Aug-2009 |
| Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results |
6-Aug-2009 |
| Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference |
5-Aug-2009 |
| Orexigen(R) Therapeutics Schedules August 6, 2009 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2009 |
4-Aug-2009 |
| Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters |
24-Jul-2009 |
| Orexigen(R) Therapeutics Prices Public Offering of Common Stock |
23-Jul-2009 |
| Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock |
22-Jul-2009 |
| -Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- |
20-Jul-2009 |
| Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results |
17-Jul-2009 |
| Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R) |
11-Jun-2009 |
| Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions |
6-Jun-2009 |
| Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings |
2-Jun-2009 |
| Orexigen(R) Therapeutics to Present at Upcoming Meetings |
13-May-2009 |
| Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy |
11-May-2009 |
| Orexigen(R) Therapeutics to Speak at Upcoming Conferences |
8-May-2009 |
| Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results |
7-May-2009 |
| Orexigen(R) Therapeutics Schedules May 7, 2009 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2009 |
5-May-2009 |
| Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program |
27-Apr-2009 |
| Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer |
31-Mar-2009 |
| Orexigen(R) Therapeutics to Speak at Cowen & Company Healthcare Conference |
16-Mar-2009 |
| OREXIGEN(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2008 Financial Results |
12-Mar-2009 |
| Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008 |
9-Mar-2009 |
| Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors |
2-Mar-2009 |
| Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference |
4-Feb-2009 |
| Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints |
8-Jan-2009 |
| Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference |
6-Jan-2009 |
| Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R) |
5-Jan-2009 |
| Orexigen(R) Therapeutics to Speak at RBC Capital Markets Investor Conference Panel |
8-Dec-2008 |
| Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team |
5-Dec-2008 |
| Orexigen(R) Therapeutics Names Eckard Weber Executive Chairman and Interim Chief Executive Officer |
10-Nov-2008 |
| Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results |
6-Nov-2008 |
| Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008 |
4-Nov-2008 |
| Orexigen(R) Therapeutics Announces Receipt of Notice of Allowance for Its Fourth U.S. Patent on Contrave(R) |
14-Oct-2008 |
| Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) |
6-Oct-2008 |
| Orexigen(R) Therapeutics Reviews Significant Data Regarding Its Obesity Product Candidates |
6-Oct-2008 |
| Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain |
2-Oct-2008 |
| Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting |
29-Sep-2008 |
| Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders |
25-Sep-2008 |
| Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences |
28-Aug-2008 |
| Orexigen(R) Therapeutics Announces Second Quarter 2008 Financial Results |
7-Aug-2008 |
| Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008 |
5-Aug-2008 |
| OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 |
29-Jul-2008 |
| Orexigen(R) Initiates Second Phase IIb Empatic™ Trial on Schedule |
9-Jul-2008 |
| Orexigen(R) Therapeutics to Discuss Two Advanced-Stage Obesity Products That Target the Brain's Critical Role in Regulating Body Weight |
12-Jun-2008 |
| Orexigen(R) Therapeutics Announces That Contrave(R) May Reverse the Incidence of Metabolic Syndrome |
7-Jun-2008 |
| Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences |
4-Jun-2008 |
| Orexigen(R) Therapeutics Issued a Key U.S. Patent Covering Composition of Contrave(R) into 2025 |
27-May-2008 |
| Orexigen(R) Therapeutics Announces First Quarter 2008 Financial Results |
8-May-2008 |
| Orexigen(R) Therapeutics Announces Completion of Patient Enrollment in Phase III Clinical Program for Contrave(R) |
7-May-2008 |
| Orexigen(R) Therapeutics to Announce First Quarter 2008 Financial Results on May 8, 2008 at 5:00 p.m. Eastern |
6-May-2008 |
| Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences |
5-May-2008 |
| Orexigen(R) Therapeutics Announces Completion of Enrollment in Second of Four Phase III Clinical Trials for Contrave(R) |
22-Apr-2008 |
| OREXIGEN™ Therapeutics Announces Fourth Quarter and Year Ended December 31, 2007 Financial Results |
13-Mar-2008 |
| OREXIGEN™ Therapeutics to Present at Upcoming Investor Conferences |
12-Mar-2008 |
| OREXIGEN™ Therapeutics to Announce Fourth Quarter and Full-Year 2007 Financial Results in Webcast March 13, 2008 |
11-Mar-2008 |
| OREXIGEN™ Therapeutics Appoints Carol Baum as Vice President of Commercialization |
10-Mar-2008 |
| OREXIGEN™ Therapeutics Announces European Patent Office Allows Composition and Use Claims for its Patent on Contrave™ to Treat Obesity |
28-Feb-2008 |
| OREXIGEN™ Therapeutics Announces Notice of Allowance for U.S. Patent Strengthening Exclusivity for Empatic™ for Obesity |
21-Feb-2008 |
| OREXIGEN™ Therapeutics Announces Exercise of Overallotment Option by Underwriters |
7-Feb-2008 |
| OREXIGEN™ Therapeutics to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference |
31-Jan-2008 |
| OREXIGEN™ Therapeutics Announces Notice of Allowance for U.S. Patent Extending Exclusivity for Composition of Contrave™ to 2024 |
31-Jan-2008 |
| Orexigen Therapeutics Announces Pricing of Its Follow-on Offering |
24-Jan-2008 |
| OREXIGEN™ Therapeutics Reports 48-Week Results of Phase IIb Trial of Empatic™ to Treat Obesity |
7-Jan-2008 |
| OREXIGEN™ Therapeutics Files Registration Statement for Proposed Follow-On Offering |
7-Jan-2008 |
| OREXIGEN™ Therapeutics Initiates Fourth Phase III Trial for Contrave™ to Treat Obesity |
11-Dec-2007 |
| OREXIGEN™ Therapeutics to Webcast Analyst & Investor Day |
29-Nov-2007 |
| OREXIGEN™ Therapeutics Added to NASDAQ Biotechnology Index |
12-Nov-2007 |
| OREXIGEN™ Therapeutics Announces Third Quarter 2007 Financial Results |
8-Nov-2007 |
| CORRECTING and REPLACING OREXIGEN™ Therapeutics Schedules November 8, 2007 Webcast Discussion of Third Quarter Financial Results |
5-Nov-2007 |
| OREXIGEN™ Therapeutics to Present Data Supporting Novel, PreClinical Drug Combination for Schizophrenia |
1-Nov-2007 |
| OREXIGEN™ Therapeutics to Present at Upcoming Investor Conferences |
30-Oct-2007 |
| OREXIGEN™ Therapeutics Reports Preclinical Results Showing Contrave™ Acts on Specific Pathways in the Brain to Reduce Food Intake |
23-Oct-2007 |
| OREXIGEN™ Therapeutics Reports Detailed Results of Phase IIb Trial of Empatic™ to Treat Obesity |
21-Oct-2007 |
| OREXIGEN™ Therapeutics Reports a Summary of Results from the Phase IIb Trial of Contrave™ to Treat Obesity |
21-Oct-2007 |
| Orexigen™ Therapeutics to Present Data on Contrave™ and Empatic™ at The Obesity Society's 2007 Annual Scientific Meeting |
18-Oct-2007 |
| OREXIGEN™ Therapeutics Initiates its Third Phase III Trial for Contrave™ to Treat Obesity |
17-Oct-2007 |
| OREXIGEN™ Therapeutics to Present at Upcoming Investor Conferences |
4-Oct-2007 |
| Orexigen™ Announces Positive Clinical Results of Its Proprietary Naltrexone Sustained Release Formulation for Use in Contrave™ |
25-Sep-2007 |
| Orexigen™ Announces Settlement Agreement with Eisai |
19-Sep-2007 |
| OREXIGEN™ Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference |
5-Sep-2007 |
| OREXIGEN™ Therapeutics Announces Second Quarter 2007 Financial Results |
9-Aug-2007 |
| OREXIGEN™ Therapeutics Schedules August 9, 2007 Webcast Discussion of Second Quarter Financial Results |
7-Aug-2007 |
| OREXIGEN™ Therapeutics to Present CONTRAVE™ Clinical Summary at CBI's 3rd Annual Obesity Drug Development Summit |
27-Jul-2007 |
| OREXIGEN™ Therapeutics Reports Top-line 24 Week Results for Phase IIb Trial of EMPATIC™ to Treat Obesity |
24-Jul-2007 |
| OREXIGEN™ Therapeutics Appoints Heather Turner as General Counsel |
10-Jul-2007 |
| OREXIGEN™ Therapeutics Added to Russell 2000 Index |
25-Jun-2007 |
| OREXIGEN™ Therapeutics Reports CONTRAVE™ Has Positive Effect on Visceral Fat and Insulin Resistance, Factors Believed to Contribute to the Risk of Heart Disease and Type II Diabetes |
23-Jun-2007 |
| OREXIGEN™ Therapeutics to Present Data on CONTRAVE™ Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23 |
21-Jun-2007 |
| OREXIGEN™ Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation |
7-Jun-2007 |
| OREXIGEN™ Therapeutics Announces First Quarter 2007 Financial Results |
25-May-2007 |
| OREXIGEN™ Therapeutics Initiates CONTRAVE™ Phase III Clinical Trials |
22-May-2007 |
| OREXIGEN™ Therapeutics Completes Initial Public Offering |
1-May-2007 |
| OREXIGEN™ Therapeutics Announces Pricing of its Initial Public Offering |
26-Apr-2007 |
| OREXIGEN™ Therapeutics files registration statement for proposed initial public offering |
19-Dec-2006 |
| OREXIGEN™ Therapeutics Completes $30 Million Series C Financing |
22-Nov-2006 |
| OREXIGEN™ Therapeutics Announces Issuance of Broad Patents Covering Composition of its Lead Anti-Obesity Compounds |
9-Nov-2006 |
| OREXIGEN™ Therapeutics Reports Positive Phase II Results for EMPATIC™ Combination-Therapy to Treat Obesity |
22-Oct-2006 |
| OREXIGEN™ Therapeutics Expands Senior Management Team as Lead Products Advance Through Late-Stage Clinical Trials |
4-Oct-2006 |
| OREXIGEN™ Therapeutics Reports Positive 24-Week Results for CONTRAVE™ Phase IIb Obesity Trestment Study |
26-Sep-2006 |
| OREXIGEN ™ Therapeutics Utilizes Brain Pet Scans to Measure Optimal Naltrexone Dosing for Treating Obesity |
13-Sep-2006 |
| OREXIGEN™ Therapeutics Reports Positive Phase II Results for CONTRAVE™ Combination-Therapy to Treat Obesity |
10-Jun-2006 |
| OREXIGEN™ Therapeutics to Present First Clinical Results for CONTRAVE™ to Treat Obesity |
7-Jun-2006 |
| OREXIGEN ™ Therapeutics Appoints Graham Cooper as Chief Financial Officer |
24-May-2006 |
| OREXIGEN™ Therapeutics appoints Dr. Gary Tollefson CEO |
8-Mar-2006 |
 |
